 Patients with stage I and II low grade follicular lymphoma are randomised between standard therapy involved field radiotherapy and investigational therapy involved field radiotherapy and chemotherapy plus rituximab. The main endpoint is progression free survival but overall survival and the influence of t14;18 status will also be studied. 